Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial

por Komatsu, Shun-ichiro, Kayukawa, Yoko, Miyazaki, Yoko, Kaneko, Akihisa, Ikegami, Hisashi, Ishiguro, Takahiro, Nakamura, Mikiko, Frings, Werner, Ono, Natsuki, Sakata, Kiyoaki, Fujii, Toshihiko, Kishishita, Shohei, Kitazawa, Takehisa, Endo, Mika, Sano, Yuji
Publicado 2022

Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours

por Sano, Yuji, Azuma, Yumiko, Tsunenari, Toshiaki, Kayukawa, Yoko, Shinozuka, Junko, Fujii, Etsuko, Amano, Jun, Nishito, Yukari, Maruyama, Toru, Kinoshita, Yasuko, Sakamoto, Yuichiro, Yoshida, Ayae, Miyazaki, Yoko, Sato, Yuta, Teramoto-Seida, Chifumi, Ishiguro, Takahiro, Tanaka, Takayoshi, Kitazawa, Takehisa, Endo, Mika
Publicado 2022